

Apple Health PDL Archived Drug Classes

Archived Drug Classes

- ▶ ALLERGY : ANAPHYLAXIS - VASOPRESSOR SELF-INJECTABLES (No updates)
- ▶ ALLERGY : ANTIHISTAMINE- DECONGESTANTS COMBINATIONS (No updates)
- ▶ ALLERGY : ANTIHISTAMINES (No updates)
- ▶ ALLERGY : MISC (No updates)
- ▶ ALLERGY : NASAL ANTICHOLINERGICS (No updates)
- ▶ ALLERGY : NASAL ANTIHISTAMINES (No updates)
- ▶ ALLERGY : NASAL STEROIDS (No updates)
- ▶ ALLERGY : NASAL STEROIDS – IMPLANT (No updates)

Archived Drug Classes

- ▶ ANALGESICS - ANTIINFLAMMATORY : ANTIRHEUMATIC AGENTS (No updates)
- ▶ ANALGESICS : MISC – TOPICAL (No updates)
- ▶ ANALGESICS : NON-NARCOTIC (No updates)
- ▶ ANALGESICS : NON-STEROIDAL ANTIINFLAMMATORY (No updates)
- ▶ ANALGESICS : OPIOID AGONISTS - SHORT ACTING (No updates)
- ▶ ANALGESICS : OPIOID PARTIALAGONISTS (No updates)
- ▶ ANORECTAL AGENTS : RECTAL ANESTHETIC / STEROIDCOMBINATIONS (No updates)
- ▶ ANORECTAL AGENTS : RECTALSTEROIDS (No updates)

Archived Drug Classes

- ▶ ANORECTAL AGENTS : VASODILATINGAGENTS (No updates)
- ▶ ANTIANXIETY AGENTS : BENZODIAZEPINES
 - ▶ FDA requiring update to boxed warning for all benzodiazepines to include risks of abuse, misuse, addiction, physical dependence and withdrawal reactions
- ▶ ANTIANXIETY AGENTS : MISC (No updates)
- ▶ ANTIBIOTICS : AMINOGLYCOSIDES– ORAL (No updates)
- ▶ ANTIBIOTICS : AMINOPENICILLINS – INJECTABLE (No updates)
- ▶ ANTIBIOTICS : AMINOPENICILLINS – ORAL (No updates)
- ▶ ANTIBIOTICS : ANTI-INFECTIVE AGENTS - MISC – ORAL (No updates)
- ▶ ANTIBIOTICS : ANTIMYCOBACTERIAL AGENTS– ORAL
 - ▶ Sirturo (bedaquiline) now has expanded indication for use as part of a combination therapy in the treatment of adult and pediatric patients, 5 years and older and weighing at least 15 kg (previously 12-18 years of age and weighing at least 30 kg)
 - ▶ Pretomanid was FDA approved in 08/2019 and added to this class. Used for limited population- combination regimen with bedaquiline and linezolid for treatment of adults with pulmonary extensively drug resistant (SDR), treatment intolerant or nonresponsive multi-drug resistant tuberculosis (MDR-TB)

Archived Drug Classes

- ▶ ANTIBIOTICS : CEPHALOSPORINS - 1ST GENERATION – INJECTABLE (No updates)
- ▶ ANTIBIOTICS : CEPHALOSPORINS - 1ST GENERATION – ORAL (No updates)
- ▶ ANTIBIOTICS : CEPHALOSPORINS - 2ND GENERATION – INJECTABLE (No updates)
- ▶ ANTIBIOTICS : CEPHALOSPORINS - 2ND GENERATION – ORAL (No updates)
- ▶ ANTIBIOTICS : CEPHALOSPORINS - 3RD GENERATION – INJECTABLE (No updates)
- ▶ ANTIBIOTICS : CEPHALOSPORINS - 3RD GENERATION – ORAL (No updates)
- ▶ ANTIBIOTICS : CEPHALOSPORINS - 4TH GENERATION – INJECTABLE (No updates)
- ▶ ANTIBIOTICS : CEPHALOSPORINS - OTHER – INJECTABLE
 - ▶ Fetroja (cefiderocol) was FDA approved in 11/2019 and in it's own class. Indicated for patients 18 years of age or older for treatment of complicated urinary tract infection (cUTI) including pyelonephritis, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)

Archived Drug Classes

- ▶ ANTIBIOTICS : FLUOROQUINOLONES – ORAL
 - ▶ Baxdela (delafloxacin) now has expanded indication for community acquired bacterial pneumonia (CABP), previously only for acute bacterial skin and skin structure infections (ABSSSI)
- ▶ ANTIBIOTICS : GLYCOPEPTIDES – ORAL (No updates)
- ▶ ANTIBIOTICS : LEPROSTATICS – ORAL (No updates)
- ▶ ANTIBIOTICS : LINCOSAMIDES – ORAL (No updates)
- ▶ ANTIBIOTICS : MACROLIDES – ORAL (No updates)
- ▶ ANTIBIOTICS : NATURAL PENICILLINS – INJECTABLE (No updates)
- ▶ ANTIBIOTICS : NATURAL PENICILLINS – ORAL (No updates)
- ▶ ANTIBIOTICS : OXAZOLIDINONES – ORAL
 - ▶ Sivextro (tedizolid phosphate) now has expanded age indication for use in patients 12 years of age and older for ABSSSI, previously only for use in adults

Archived Drug Classes

- ▶ ANTIBIOTICS : PENICILLIN COMBINATIONS – INJECTABLE (No updates)
- ▶ ANTIBIOTICS : PENICILLIN COMBINATIONS – ORAL (No updates)
- ▶ ANTIBIOTICS : PENICILLINASE-RESISTANT PENICILLINS – ORAL (No updates)
- ▶ ANTIBIOTICS : SULFONAMIDES – INJECTABLE (No updates)
- ▶ ANTIBIOTICS : SULFONAMIDES – ORAL (No updates)
- ▶ ANTIBIOTICS : TETRACYCLINES – INJECTABLE (No updates)
- ▶ ANTIBIOTICS : TETRACYCLINES – ORAL (No updates)
- ▶ ANTIBIOTICS : TOPICAL (No updates)

Archived Drug Classes

- ▶ ANTIBIOTICS : VAGINAL (No updates)
- ▶ ANTICOAGULANTS : COUMARIN ANTICOAGULANTS (No updates)
- ▶ ANTICOAGULANTS : HEPARINS AND HEPARINOID-LIKE AGENTS (No updates)
- ▶ ANTICONVULSANTS : BENZODIAZEPINES – ORAL
 - ▶ FDA requiring update to boxed warning for all benzodiazepines to include risks of abuse, misuse, addiction, physical dependence and withdrawal reactions
- ▶ ANTICONVULSANTS : CARBAMATES
 - ▶ Xcopri (cenobamate) was added to the class, was FDA approved in 11/2019 however was pending controlled substance scheduling and received Schedule V designation in 03/2020
- ▶ ANTICONVULSANTS : GABA MODULATORS (No updates)
- ▶ ANTICONVULSANTS : HYDANTOINS (No updates)
- ▶ ANTICONVULSANTS : VALPROIC ACID (No updates)

Archived Drug Classes

▶ Recommendation:

- ▶ All drug classes listed on slides 2 through 8 are eligible for archiving at the discretion of HCA.
- ▶ Products in these drug classes may require prior authorization to determine medical necessity
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Archived Drug Classes

▶ **Motion:** I move that all drug classes listed on slides 2 through 8 are eligible for archiving at the discretion of HCA. Products in these drug classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

▶ **Motion:**

▶ **2nd:**